September 28, 1999
Maxygen Announces $6.7 Million Grant from DARPA to Develop Aerosolized Vaccines
Redwood City, Calif., September 28, 1999 – Maxygen, Inc. announced today that it has received a $6.7 million three-year grant from the Defense Advanced Research Agency (DARPA) to use its proprietary MolecularBreeding™ directed evolution technology (also known as "DNA Shuffling") to develop aerosol-based vaccines to protect against a broad spectrum of pathogens.
Aerosol delivery of prophylactic and therapeutic agents is potentially the simplest and most cost-effective way to protect or treat humans and animals from disease epidemics. In addition to this recent DARPA grant, Maxygen is the recipient of two additional DARPA grants in the vaccine area. In February 1998, Maxygen received a $5.6 million grant to evolve novel DNA vectors for efficient delivery and expression of pathogen antigens, and in April 1999, the Company received a grant of $7.7 million to generate novel vaccine antigens for a wide range of pathogens.
Maxygen, Inc., headquartered in Redwood City, CA is a private biotechnology company that is focused on the development of novel and improved commercial products using its proprietary MolecularBreeding™ directed evolution technology for a variety of industries including human therapeutics, chemicals, vaccines, industrial enzymes, and agriculture. The Company is the leader in nucleic acid recombination technologies for imparting new properties into single genes, multi-gene systems, pathways, vectors and genomes. Maxygen has commercial relationships with several companies including Novo Nordisk in certain areas of industrial enzymes, Pioneer Hi-Bred and ZenecaAgrochemicals for specific products in agriculture and DSM Anti-Infectives for improved manufacturing of certain classes of penicillin antibiotics. Maxygen was founded in a March 1997 spinout from Glaxo Wellcome-Affymax, led by biotech entrepreneur Alejandro Zaffaroni, and MolecularBreeding™ inventor Pim Stemmer.
Return to News